CLINICAL RESEARCH
Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease
A Randomized Controlled Trial
David E. Kandzari, MD, FACC*,*,
Martin B. Leon, MD, FACC ,
Jeffrey J. Popma, MD, FACC ,
Peter J. Fitzgerald, MD, FACC||,
Charles O'Shaughnessy, MD, FACC#,
Michael W. Ball, MD, FACC**,
Mark Turco, MD, FACC ,
Robert J. Applegate, MD, FACC,
Paul A. Gurbel, MD, FACC,
Mark G. Midei, MD, FACC,
Sejal S. Badre, MS,
Laura Mauri, MD, MSc, FACC,
Kweli P. Thompson, MD¶,
LeRoy A. LeNarz, MD¶,
Richard E. Kuntz, MD, FACC¶ for the ENDEAVOR III Investigators
* Duke Clinical Research Institute, Durham, North Carolina USA
Baptist Medical Center and Wake Forest University, Winston-Salem, North Carolina
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Harvard Clinical Research Institute and Brigham and Women's Hospital, Boston, Massachusetts
|| Stanford University Medical Center, Palo Alto, California, USA
¶ Medtronic, Inc., Santa Rosa, California
# North Ohio Heart Center, Elyria, Ohio
** St. Vincent's Hospital, Indianapolis, Indiana
Washington Adventist Hospital, Takoma Park, MarylandUSA
Sinai Center for Thrombosis Research, Baltimore, MarylandUSA
St. Joseph's Medical Center, Towson, Maryland
Manuscript received March 24, 2006;
revised manuscript received August 7, 2006,
accepted August 7, 2006.
* Reprint requests and correspondence: Dr. David E. Kandzari, Room 7063, Duke Clinical Research Institute, 2400 Pratt Street, Durham, North Carolina 27705. (Email: david.kandzari{at}duke.edu).
OBJECTIVES: This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES).
BACKGROUND: Whether a cobalt-based alloy stent coated with the novel antiproliferative agent, zotarolimus, and a phosphorylcholine polymer may provide similar angiographic and clinical benefit compared with SES is undetermined.
METHODS: A prospective, multicenter, 3:1 randomized trial was conducted to evaluate the safety and efficacy of ZES (n = 323) relative to SES (n = 113) in 436 patients undergoing elective percutaneous revascularization of de novo native coronary lesions with reference vessel diameters between 2.5 mm and 3.5 mm and lesion length  14 mm and  27 mm. The primary end point was 8-month angiographic in-segment late lumen loss.
RESULTS: Angiographic in-segment late lumen loss was significantly higher among patients treated with ZES compared with SES (0.34 ± 0.44 mm vs. 0.13 ± 0.32 mm, respectively; p < 0.001). In-hospital major adverse cardiac events were significantly lower among patients treated with ZES (0.6% vs. 3.5%, p = 0.04). In-segment binary angiographic restenosis was also higher in the ZES cohort (11.7% vs. 4.3%, p = 0.04). Total (clinically and non-clinically driven) target lesion revascularization rates at 9 months were 9.8% and 3.5% for the ZES and SES groups, respectively (p = 0.04). However, neither clinically driven target lesion revascularization (6.3% zotarolimus vs. 3.5% sirolimus, p = 0.34) nor target vessel failure (12.0% zotarolimus vs. 11.5% sirolimus, p = 1.0) differed significantly.
CONCLUSIONS: Compared with SES, treatment with a phosphorylcholine polymer-based ZES is associated with significantly higher late lumen loss and binary restenosis at 8-month angiographic follow-up.
(The Endeavor III CR; http://clinicaltrials.gov/ct/show/NCT00265668
[ClinicalTrials.gov]
?order=1?)
|
Abbreviations and Acronyms
| | CK = creatine kinase | | IVUS = intravascular ultrasound | | MACE = major adverse cardiac events | | MLD = minimal lumen diameter | | SES = sirolimus-eluting stent | | ZES = zotarolimus-eluting stent |
|
This article has been cited by other articles:
|
|
|
|
 
G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 9, 2012;
(2012)
ehr479v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, C. S. Barker, M. B. Leon, L. Mauri, W. Wijns, J. Fajadet, and R. Mehran
Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1119 - 1128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Kim, D. Wallace-Bradley, C. L. Alviar, G. Conditt, K. Milewski, M. E. Afari, Y. Cheng, C. Gallego, A. Tellez, G. W. Stone, et al.
Correlation of Angiographic Late Loss With Neointimal Proliferation in Stents Evaluated by OCT and Histology in Porcine Coronary Arteries
J. Am. Coll. Cardiol. Img.,
September 1, 2011;
4(9):
1002 - 1010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Brott
Linking Drug-Eluting Stent Kinetics and Clinical Outcomes: Insights From Optical Coherence Tomography
J. Am. Coll. Cardiol. Intv.,
July 1, 2011;
4(7):
786 - 788.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fujii, D. Kawasaki, K. Oka, H. Akahori, M. Fukunaga, H. Sawada, M. Masutani, M. Lee-Kawabata, T. Tsujino, M. Ohyanagi, et al.
Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation
Heart,
June 15, 2011;
97(12):
977 - 982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Pilgrim, L. Raber, A. Limacher, L. Loffel, P. Wenaweser, S. Cook, J.-C. Stauffer, M. Togni, R. Vogel, A. Garachemani, et al.
Comparison of Titanium-Nitride-Oxide-Coated Stents With Zotarolimus-Eluting Stents for Coronary Revascularization: A Randomized Controlled Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2011;
4(6):
672 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, P. Juni, E. Nuesch, B. Kalesan, P. Wenaweser, A. Moschovitis, A. A. Khattab, M. Bahlo, M. Togni, S. Cook, et al.
Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
J. Am. Coll. Cardiol.,
May 24, 2011;
57(21):
2143 - 2151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, L. Mauri, J. J. Popma, M. A. Turco, P. A. Gurbel, P. J. Fitzgerald, and M. B. Leon
Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Bates and D. S. Menees
My Stent Is Better Than Your Stent...Or Is It?
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
551 - 553.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Kang, G. S. Mintz, D.-W. Park, S.-W. Lee, Y.-H. Kim, C. W. Lee, K.-H. Han, J.-J. Kim, S.-W. Park, and S.-J. Park
Comparison of Zotarolimus-Eluting Stents With Sirolimus-Eluting and Paclitaxel-Eluting Stents: Intimal Hyperplasia and Vascular Changes Assessed by Volumetric Intravascular Ultrasound Analysis
Circ Cardiovasc Interv,
April 1, 2011;
4(2):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, M. Nakano, F. Otsuka, J. N. Wilcox, R. Melder, S. Pruitt, F. D. Kolodgie, and R. Virmani
Evaluation of Polymer-Based Comparator Drug-Eluting Stents Using a Rabbit Model of Iliac Artery Atherosclerosis
Circ Cardiovasc Interv,
February 1, 2011;
4(1):
38 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, J. M. Massaro, S. Jiang, I. Meredith, W. Wijns, J. Fajadet, D. E. Kandzari, M. B. Leon, D. E. Cutlip, and K. P. Thompson
Long-Term Clinical Outcomes With Zotarolimus-Eluting Versus Bare-Metal Coronary Stents
J. Am. Coll. Cardiol. Intv.,
December 1, 2010;
3(12):
1240 - 1249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Park, Y.-H. Kim, S.-C. Yun, S.-J. Kang, S.-W. Lee, C.-W. Lee, S.-W. Park, I.-W. Seong, J.-H. Lee, S.-J. Tahk, et al.
Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization: The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial
J. Am. Coll. Cardiol.,
October 5, 2010;
56(15):
1187 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. de la Torre Hernandez, F. Alfonso, F. Gimeno, J. A. Diarte, R. Lopez-Palop, A. Perez de Prado, F. Rivero, J. Sanchis, M. Larman, J. F. Diaz, et al.
Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice: Results From the Multicenter Spanish Registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)
J. Am. Coll. Cardiol. Intv.,
September 1, 2010;
3(9):
911 - 919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Jain, C. Lotan, I. T. Meredith, F. Feres, R. Zambahari, N. Sinha, M. T. Rothman, and for the E-Five Registry Investigators
Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry
Heart,
June 1, 2010;
96(11):
848 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. George, D. J. Moliterno, and G. D. Dangas
American College of Cardiology Annual Scientific Session 2010: Update in Interventional Cardiology
J. Am. Coll. Cardiol. Intv.,
May 1, 2010;
3(5):
562 - 564.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, L. Mauri, J. J. Popma, D. E. Cutlip, E. Nikolsky, C. O'Shaughnessy, P. A. Overlie, B. T. McLaurin, S. L. Solomon, J. S. Douglas Jr, et al.
A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From the ENDEAVOR IV Trial
J. Am. Coll. Cardiol.,
February 9, 2010;
55(6):
543 - 554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ohman and R. M. Califf
When Can Noninferior Be Superior?: The Multidimensional Nature of Clinical Decision-Making Calls for Innovative Approaches to Clinical Trials
J. Am. Coll. Cardiol.,
February 9, 2010;
55(6):
555 - 557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Eisenstein, M. B. Leon, D. E. Kandzari, L. Mauri, R. Edwards, D. F. Kong, P. A. Cowper, K. J. Anstrom, and for the ENDEAVOR III Investigators
Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent: 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1199 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, D. E. Kandzari, E. L. Eisenstein, K. J. Anstrom, L. Mauri, D. E. Cutlip, E. Nikolsky, C. O'Shaughnessy, P. A. Overlie, A. J. Kirtane, et al.
Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions: 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1208 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotan, I. T. Meredith, L. Mauri, M. Liu, M. T. Rothman, and for the E-Five Investigators
Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice: 12-Month Data From the E-Five Registry
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1227 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mukherjee and D. J. Moliterno
Second-Generation Drug-Eluting Stents and the Continuous Need for Rapidly Available Real-World Data
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1236 - 1239.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Kim, I.-K. Jang, C. Fan, T. H. Kim, J.-S. Kim, S. M. Park, E.-Y. Choi, S. H. Lee, Y.-G. Ko, D. Choi, et al.
Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1240 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J-S Kim, I-K Jang, J-S Kim, T H Kim, M Takano, T Kume, N W Hur, Y-G Ko, D Choi, M-K Hong, et al.
Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
Heart,
December 1, 2009;
95(23):
1907 - 1912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane, R. Patel, C. O'Shaughnessy, P. Overlie, B. McLaurin, S. Solomon, L. Mauri, P. Fitzgerald, J. J. Popma, D. E. Kandzari, et al.
Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial: Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
967 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. T. Meredith, S. Worthley, R. Whitbourn, D. L. Walters, D. McClean, M. Horrigan, J. J. Popma, D. E. Cutlip, A. DePaoli, M. Negoita, et al.
Clinical and Angiographic Results With the Next-Generation Resolute Stent System: A Prospective, Multicenter, First-in-Human Trial
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
977 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chevalier, S. Silber, S.-J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann, W. Wijns, M.-C. Morice, et al.
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne, J. Mehilli, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, A. Schomig, A. Kastrati, and for the Intracoronary Stenting and Angiographic Re
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents
Eur. Heart J.,
April 2, 2009;
30(8):
923 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
226 - 232.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chevalier, C. Di Mario, F.-J. Neumann, F. Ribichini, P. Urban, J. J. Popma, P. J. Fitzgerald, D. E. Cutlip, D. O. Williams, J. Ormiston, et al.
A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
524 - 532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. van der Hoeven, S.-S. Liem, J. Dijkstra, S. C. Bergheanu, H. Putter, M. L. Antoni, D. E. Atsma, M. Bootsma, K. Zeppenfeld, J. W. Jukema, et al.
Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Acute and 9-Month Intravascular Ultrasound Results of the MISSION! Intervention Study
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
192 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al.
Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
23 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl.,
August 1, 2007;
9(suppl_D):
D10 - D19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Circulation,
July 17, 2007;
116(3):
316 - 328.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
